Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 38 clinical trials
Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil

. Cyclosporine may help irinotecan work better by making tumor cells more sensitive to the drug. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the

monoclonal antibodies
irinotecan
tumor cells
panitumumab
metastatic colorectal cancer
  • 129 views
  • 07 Nov, 2020
  • 12 locations
Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients

National trial, multicenter, randomized, phase II assessing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from

modified folfox6
irinotecan
adenocarcinoma
folfirinox
panitumumab
  • 15 views
  • 28 Mar, 2021
  • 9 locations
First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS

The association of FOLFOX (5-fluoruracil, folinic acid, and oxaliplatin) and pan is a standard option for the first-line treatment of unresectable RAS and BRAF wt mCRC patients. The phase III TRIBE trial recently demonstrated that FOLFOXIRI (5-fluoruracil, folinic acid, oxaliplatin and irinotecan) plus bev significantly prolongs PFS and OS and …

oxaliplatin/irinotecan
levoleucovorin
leucovorin
cetuximab
folfiri regimen
  • 20 views
  • 23 Jan, 2021
  • 4 locations
Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR

RAS-wild upon retesting will receive rechallenge with panitumumab and chemotherapy

metastatic adenocarcinoma
irinotecan
adenocarcinoma
bevacizumab
panitumumab
  • 0 views
  • 26 Jan, 2021
  • 1 location
Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer

This clinical study will investigate the utility of PET imaging with [89Zr]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement

EGFR
cancer
  • 0 views
  • 25 Jan, 2021
  • 1 location
  • 0 views
  • 14 Feb, 2021
  • 6 locations
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

The study will use previously established doses of panitumumab or cetuximab in the metastatic setting for the treatment of unresectable colorectal cancer (CRC). It is designed to investigate an

  • 0 views
  • 26 Jan, 2021
  • 1 location
FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

Single-arm, multi-centre phase II study The primary objective is to evaluate the time to failure of the strategy.

colorectal adenocarcinoma
adenocarcinoma
panitumumab
folfox regimen
neutrophil count
  • 19 views
  • 05 Mar, 2021
  • 47 locations
Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) Therapy

The analysis of circulating DNA (Deoxyribonucleic acid) to identify potential resistance mechanisms during anti-EGFR (epidermal growth factor receptor) treatment is of great interest, as evidenced by the recent journal published by Corcoran in the prestigious New England Journal of Medicine. EmutRAS is one of the first studies that will specifically …

irinotecan
rat sarcoma
folfirinox
panitumumab
EGFR
  • 1 views
  • 15 Feb, 2021
  • 2 locations
iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer

This is a single-arm, single centre open-label, phase II interventional clinical trial of combination immunotherapy with Nivolumab and Relatlimab in mCRC.

adenocarcinoma
nivolumab
measurable disease
  • 11 views
  • 24 Jan, 2021
  • 1 location